市场快照
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| CAGR: | 17.3 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
伴随诊断市场的增长可归因于对个性化医疗的日益关注以及药物和诊断技术的共同开发。此外，与药物相关的药物不良反应病例不断增加，推动了对伴随诊断的需求。欧洲市场受到多种因素的推动，例如药物疗效/安全性的提高、药物监管审批速度加快、医疗保健支出和药物开发成本降低，以及市场参与者与政府组织之间的合作伙伴关系增加。
由于伴随诊断的出现，肿瘤学是受益匪浅的主要领域之一。伴随诊断在识别具有可预测反应的特定生物标志物的患者方面非常有益。伴随诊断能够预测针对特定人的任何特定疗法的反应，这反过来又会导致更好的患者治疗并减少医疗保健支出。
报告范围
伴随诊断是指与一种治疗药物一起进行的补充测试，以分析其对个体的可及性和有效性。伴随诊断测试提供的信息对于安全有效地使用相应的药物或生物制品至关重要。
| By Technology | |
| Immunohistochemistry (IHC) | |
| Polymerase Chain Reaction (PCR) | |
| In-situ Hybridization (ISH) | |
| Real-time PCR (RT-PCR) | |
| Gene Sequencing | |
| Other Technologies |
| By Indication | |
| Lung Cancer | |
| Breast Cancer | |
| Colorectal Cancer | |
| Leukemia | |
| Melanoma | |
| Other Indications |
| Geography | ||||||||
|
主要市场趋势
免疫组织化学部分预计将在预测期内实现强劲增长。
免疫组织化学 (IHC) 是通过利用抗体与特定抗原结合的原理检测组织细胞中的抗原或蛋白质的过程。为伴随诊断开发严格的 IHC 分析，特别是跨肿瘤药物管道，已成为许多顶级制药公司的重要步骤和优先事项。使用治疗性人源化单克隆抗体曲妥珠单抗治疗转移性乳腺癌，是第一个涉及基于 IHC 的伴随诊断，即基因泰克（罗氏）销售的 Hercep 测试。该测试用于识别过度表达 HER-2 受体的患者，从而针对可能对所用药物显示临床疗效的特定患者组。
To understand key trends, Download Sample Report
竞争格局
市场由少数主要基于技术创新进行竞争的全球参与者主导。主要市场参与者包括 Abbott Laboratories、Agilent Technologies、Beckman Coulter Inc.（Danaher Corporation）、BioMerieux SA、F. Hoffmann-La Roche AG、Qaigen Inc.、Siemens Healthineers 和 Thermo Fisher Scientific Inc. 等。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Demand for Personalized Medicine and Targeted Therapy
-
4.2.2 Co-development of Drug and Diagnostic Technology
-
-
4.3 Market Restraints
-
4.3.1 High Cost of Drug Development and Associated Clinical Trials
-
4.3.2 Reimbursement Issues
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Technology
-
5.1.1 Immunohistochemistry (IHC)
-
5.1.2 Polymerase Chain Reaction (PCR)
-
5.1.3 In-situ Hybridization (ISH)
-
5.1.4 Real-time PCR (RT-PCR)
-
5.1.5 Gene Sequencing
-
5.1.6 Other Technologies
-
-
5.2 By Indication
-
5.2.1 Lung Cancer
-
5.2.2 Breast Cancer
-
5.2.3 Colorectal Cancer
-
5.2.4 Leukemia
-
5.2.5 Melanoma
-
5.2.6 Other Indications
-
-
5.3 Geography
-
5.3.1 Europe
-
5.3.1.1 Germany
-
5.3.1.2 United Kingdom
-
5.3.1.3 France
-
5.3.1.4 Italy
-
5.3.1.5 Spain
-
5.3.1.6 Rest of Europe
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Abbott Laboratories
-
6.1.2 Agilent Technologies
-
6.1.3 Beckman Coulter Inc. (Danaher Corporation)
-
6.1.4 BioMerieux SA
-
6.1.5 F. Hoffmann-La Roche AG
-
6.1.6 Qaigen Inc.
-
6.1.7 Siemens Healthineers
-
6.1.8 Thermo Fisher Scientific Inc.
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Europe Companion Diagnostics Market market is studied from 2018 - 2026.
What is the growth rate of Europe Companion Diagnostics Market?
The Europe Companion Diagnostics Market is growing at a CAGR of 17.3% over the next 5 years.
Who are the key players in Europe Companion Diagnostics Market?
Abbott Laboratories, Agilent Technologies, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Qaigen Inc. are the major companies operating in Europe Companion Diagnostics Market.
